The initial combination is the starting pharmacological intervention together with lifestyle changes for the management of most components of the Cardiovascular-Kidney Metabolic Syndrome (American Heart Association; November 2023) e.g. hypertension, heart failure, dyslipidemia, and chronic kidney disease. For type 2 diabetes, the VERIFY trial (Vildagliptin/Metformin vs. Metformin; 2019) showed better outcomes for the initial combination vs. stepwise approach.
(2024). Which Initial Combination for Type 2Diabetes. Egyptian Society of Diabetes and Lipidology Journal, 4(2), -. doi: 10.21608/esdlj.2024.456245
MLA
. "Which Initial Combination for Type 2Diabetes", Egyptian Society of Diabetes and Lipidology Journal, 4, 2, 2024, -. doi: 10.21608/esdlj.2024.456245
HARVARD
(2024). 'Which Initial Combination for Type 2Diabetes', Egyptian Society of Diabetes and Lipidology Journal, 4(2), pp. -. doi: 10.21608/esdlj.2024.456245
VANCOUVER
Which Initial Combination for Type 2Diabetes. Egyptian Society of Diabetes and Lipidology Journal, 2024; 4(2): -. doi: 10.21608/esdlj.2024.456245
)
